A potent inhibitor of SGLT2 (Kis = 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2, respectively); selective for SGLT2 (IC50 = 2.9 nM) over other SGLTs (IC50s = >1,500 nM for SGLT1 and 3-6); reduces plasma glucose concentration and increases renal glucose clearance in Zucker diabetic fatty rats in a dose-dependent manner when administered at doses ranging from 3-10 mg/kg; reduces hyperglycemia in non-fasted db/db mice and decreases postprandial hyperglycemia in GK rats, a non-obese model of type 2 diabetes with glucose intolerance,